Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 70Lymphoma 54Lymphoma, Large B-Cell, Diffuse 40Precursor Cell Lymphoblastic Leukemia-Lymphoma 29Hodgkin Disease 26Sarcoma 25Lymphoma, Follicular 25Lymphoma, Non-Hodgkin 24Leukemia 19Burkitt Lymphoma 17Multiple Myeloma 16Endometrial Neoplasms 15Neuroblastoma 14Ovarian Neoplasms 12Carcinoma, Hepatocellular 12Lymphoma, Large-Cell, Immunoblastic 11Lymphoma, Mantle-Cell 10Liposarcoma 9Neoplasms 8Lymphoma, Large-Cell, Anaplastic 8Leiomyosarcoma 8Histiocytoma, Malignant Fibrous 8Urinary Bladder Neoplasms 7Lymphoma, B-Cell, Marginal Zone 7Hemangiosarcoma 7Fibrosarcoma 7Wilms Tumor 6Triple Negative Breast Neoplasms 6Sarcoma, Synovial 6Neurofibrosarcoma 6

Interventions

Docetaxel 3Cyclophosphamide 3Paclitaxel 2Epirubicin 2Tamoxifen 1Fluorouracil 1Doxorubicin 1CP protocol 1Anthracyclines 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Primary Breast Cancer × Doxorubicin × Clear all
NCT00793377 2008-11-19

Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Docetaxel (AC-Doc) Versus Dose-Dense Doxorubicin and Docetaxel (ADoc) in Breast Cancer

GBG Forschungs GmbH

Phase 3 Completed
913 enrolled
Breast

Primary Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡